Christopher Moxham
Directeur Général chez Rarebase, PBC
Postes actifs de Christopher Moxham
Sociétés | Poste | Début | Fin |
---|---|---|---|
Rarebase, PBC
Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Directeur Général | 04/10/2023 | - |
President | 13/07/2023 | - | |
Directeur Technique/Scientifique/R&D | - | 04/10/2023 |
Historique de carrière de Christopher Moxham
Anciens postes connus de Christopher Moxham
Sociétés | Poste | Début | Fin |
---|---|---|---|
ELI LILLY AND COMPANY | Corporate Officer/Principal | - | - |
FULCRUM THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 05/02/2021 | - |
Corporate Officer/Principal | 01/01/2019 | 05/02/2021 |
Formation de Christopher Moxham
Cornell University | Undergraduate Degree |
Stony Brook University | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectorielle
Consumer Services | 3 |
Health Technology | 3 |
Technology Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
FULCRUM THERAPEUTICS, INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
Entreprise privées | 1 |
---|---|
Rarebase, PBC
Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Technology Services |
- Bourse
- Insiders
- Christopher Moxham
- Expérience